Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase II pazopanib trial in urothelial cancer closed due to lack of activity

Feb. 28, 2011

NCI develops anticancer monoclonal antibodies targeting mesothelin

Feb. 28, 2011

Additional phase II data reported on paclitaxel nanoparticles in urothelial cancer

Feb. 28, 2011

CD151 antigen is a marker of prostate cancer recurrence after radical prostatectomy

Feb. 25, 2011

Epidermal growth factor receptor may be marker of progression of penile squamous cancer

Feb. 25, 2011

BMS-936558 shows promise in RCC and mCRPC in phase I trial

Feb. 25, 2011

AR-42 displays potent antitumor effects in models of embryonal carcinoma

Feb. 25, 2011

Intraprostatic administration of PROSTVAC VF cancer vaccine is feasible and safe

Feb. 24, 2011

Interim phase I data support safety of tremelimumab plus bicalutamide in recurrent prostate cancer

Feb. 24, 2011

PSMA-ADC appears safe in first-in-human study in taxane-refractory metastatic CRPC

Feb. 24, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...